ReviewCancer cell international2026
Clonal hematopoiesis in the pathogenesis of non-hematologic diseases with therapeutic potential.
Review in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clonal hematopoiesis (CH) — clonal expansion of hematopoietic stem or progenitor cells due to somatic mutation — is associated with increased pathogenic risk and inferior clinical outcome of multiple diseases other than hematological diseases, such as cardiovascular diseases, solid tumors, kidney diseases, chronic liver diseases, and neurodegenerative diseases, as evidenced by many cohort studies. Of note, advanced knowledge about the underlying mechanisms of how CH specifically affects these diseases, including clonal expansion and abnormal hematopoiesis, immune dysregulation, chromosome aberration, genomic instability and epigenetic regulation, which identifies novel therapeutic targets and provides important rationale for treatment strategies. Here, we focused on the pathogenic role of CH in non-hematologic diseases and comprehensively reviewed recent researches on the pathogenic mechanisms of CH to provide a systematic and global view of CH-related pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.